With the continuous maturity and landing of artificial intelligence technology, AI-assisted doctors' treatment has long been common in medical institutions in China. At the "two sessions" held this year, the application of artificial intelligence in the medical field has also "respected the expectations" and continues to be the focus of attention of the two sessions this year.
Recently, IBM and Baiyang Intelligent Technology Co., Ltd. held a press conference in Beijing. The two parties jointly announced that Watson for Oncology (hereinafter referred to as "WfO") will have an exclusive total distribution rights for three years in the Chinese market for eight years. At the same time, both parties will Fully integrate superior resources, establish comprehensive and deep strategic partnerships, and continue to promote the development of China's smart healthcare. Baiyang Pharmaceutical Group Chairman Fu Gang, Baiyang Intelligent Technology CEO Li Qin, Chief Marketing Officer Wang Biquan, US Baiyang Investment General Manager Li Dongning, IBM Watson Health Global Tumor and Life Sciences Division General Manager Lisa Rometty, Global Sales Vice Representatives such as President Zaher EI-Assi attended the meeting and accepted interviews with media such as Yiou Health.
Origins from 2017, IBM Watson and Baiyang Intelligent Technology can't wait
March 28, 2017 is the first signing of Baiyang Intelligent Technology and IBM, which has obtained the exclusive total distribution rights of WfO in the Chinese market for three years. Three months later, Baiyang Intelligent Technology once again received the exclusive sales agent of Watson for Genomics in China.
As a medical information service provider under Baiyang Medicine, Baiyang Intelligent Technology has set up a “three-end, two-cloud and one platform†to provide intelligent solutions for governments, hospitals, pharmaceutical companies, pharmacies, doctors and patients. . Because of its characteristics in various hospitals, clinics and other medical institutions, it has become a preferred partner for WfO in China.
The layout of Baiyang Pharmaceutical Group in the field of science and technology has become clearer with this cooperation. When signing the contract for the first time, Fu Gang mentioned that more than Baiyang Intelligent Technology, "Bodhi Medical Cloud Platform" is also a product of cooperation between Baiyang Pharmaceutical Group and IBM.
IBM Watson is a cognitive technology platform launched by IBM. From the perspective of Watson Health, the embedded technology of cognitive intelligence will help hospitals in many fields such as cancer treatment, chronic disease management, and imaging inspection. upgrade.
This coincides with the idea that Baiyang Intelligent Technology AI changes medical services, and only one year after the cooperation, it can't wait to renew. Lisa Rometty said that China's medical market is both important and complicated, so IBM pays more attention to cooperation in the Chinese market. Partner's choice. During the cooperation period, WfO has covered 65 hospitals and medical institutions in 22 provinces and 39 cities in China. According to IBM Watson, the system is widely sought after in the doctor community across the country, covering more than 150 hospitals on five continents. As of January 2018, the cumulative number of patients served reached more than 45,000.
Three steps in the future, and launched Baiyang smart doctor cloud platform
Then, when the two sides renewed their contracts for five years, what are the "big ambitions"? Fugang has introduced to the health of Yiou Ou, and nearly 70 of the WfO coverage are hospitals and medical institutions other than the first-tier cities such as Beijing and Shanghai. In the future, the cooperation between the two parties will be carried out in three steps:
First, in 2018, Baiyang Intelligent Technology will help WfO achieve “sinkingâ€, which means that more and more hospitals and medical institutions will be established next. In the country's vigorous implementation of grading diagnosis and treatment, regardless of AI+ medical awareness and demand, city and county hospitals and medical institutions are higher than the top three hospitals.
Second, there is a big trend in the future. Many new drugs for cancer will appear in DTP pharmacies, and DTP may also assume the role of giving a second diagnostic opinion. In the future, WfO will also provide data support in assisting DTP pharmacies.
Third, in medical education, WfO will also play a role. Since landing in June, IBM Watson Health has hosted 86 presidents' communication meetings, completed 6-8 clinical experience studies, and published 4 articles at international conferences. This not only allows experts and doctors to understand Watson, but also helps. Improve patient awareness of Watson. In the future, WfO's data will be further applied to advance clinical research and medical education.
Not only that, Fu Gang also revealed that Baiyang Intelligent Technology has launched the smart doctor cloud platform “BsmartDâ€, which includes tumor decision support system, intelligent image diagnosis and radiation therapy solutions, and deepens the application and landing of artificial intelligence in the medical field.
“The 5-year survival rate of cancer patients in China is currently estimated at 36.9% in 2015, compared with 70% in the US in 2012. Our vision is to achieve a five-year survival rate for cancer in China through WfO. As high as it is." Fu Gang said.
Smart medical care is “to be releasedâ€, where will the next explosion point be?
In the previous interview, Fu Gang had suggested that AI+ medical treatment can be divided into three stages: first, assisted diagnosis. This is the easiest, because as long as there is enough data, it can be calculated using the inductive algorithm. For example, in the application of images; second, adjuvant therapy. How is the operation done? Where to cut? Where is the blood vessel? To build a model, let the surgery be more accurate; third, assist decision-making, this is the most difficult. Because a team of experts from top medical institutions must be involved. â€
In recent years, domestic startups that have cut into AI+ medical care from the auxiliary diagnosis have sprung up. The most typical ones are those who do medical image recognition such as Pushing Technology, Huihui Huiying, and Yasen Technology. Auxiliary treatments such as the number of heads for medical robots are few and far between, and the decision-making threshold for technology and talent is even rare.
According to the "2016-2017 Artificial Intelligence + Medical Market Analysis and Trend Report" released by HC3i China Digital Medical Network, China is at the forefront of medical artificial intelligence: In 2016, China's artificial intelligence + medical market reached 9.661 billion yuan. The growth rate is 37.9%; in 2017, it will exceed 13 billion yuan, an increase of 40.7%; it is estimated that by 2025, the total value of artificial intelligence application market will reach 127 billion US dollars. The medical industry will account for one-fifth of the market size.
According to the health of the billion-dollar health, in addition to the well-known Watson for Oncology and Watson for Genomics, IBM Watson also has three products, IBM Watson for Drug Discovery, IBM Watson Care Manager, and Social Program Management, but it has not yet been implemented. In China's large-scale landing, so we can boldly predict that under the double breakthrough of technological breakthroughs and national policy dividends, AI+ medical care is welcoming the blasting point. In this blue ocean, there are countless sub-fields worth exploring. Enough for us to look forward to.
Optical Fingerprint Scanner,Programmable Fingerprint Scanner,Biometric Optical Fingerprint Scanner,Wireless Small Optical Fingerprint Scanner
Chongqing Huifan Technology Co., Ltd , https://www.hfsecuritytech.com